anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a method for preparing specific IgY against mutant avian influenza virus and the preparation thereof. To solve the problems in prior art, such as that the existing products can not resist mutant avian influenza virus, the finished product, i.e. specific IgY against mutant avian influenza virus, can be obtained by preparing a vaccine against mutant avian, influenza virus, innoculating avians capable of laying eggs with the vaccine, obtaining immunized eggs against avian influenza virus, extracting raw IgY from the yolks of those eggs, purifing the raw IgY, and filtering off bacteriums and viruses through, special equipments. Specifically, it may be specific IgY against mutant avian influenza virus, sepcific IgY against polypeptide HA2 of avian influenza virus, or specific IgY against the receptor of avian influenza virus. Specific complex IgY is obtained by mixing specific IgY against mutant avian influenza virus and specific IgY against secondary invader in appropriate proportion. And various preparations capable of preventing and curing avian influenza can be obtained by mixing specific IgY against mutant avian influenza virus or specific complex IgY against mutant avian influenza with, 99.99-80.0% adjuvants.
PURPOSE: To investigate the regulatory effect and mechanism of Vitamin D receptor (VDR) on mitochondrial function in renal tubular epithelial cell under diabetic status.
METHODS: The diabetic rats induced by streptozotocin (STZ) and HK-2 cells under high glocose(HG)/transforming growth factor beta (TGF-β) stimulation were used in this study. Calcitriol was administered for 24 weeks. Renal tubulointerstitial injury and some parameters of mitochondrial function including mitophagy, mitochondrial fission, mitochondrial ROS, mitochondrial membrane potential (MMP), mitochondrial ATP, Complex V activity and mitochondria-associated ER membranes (MAMs) integrity were examined. Additionally, paricalcitol, 3-MA (an autophagy inhibitor), VDR over-expression plasmid, VDR siRNA and Mfn2 siRNA were applied in vitro.
RESULTS: The expression of VDR, Pink1, Parkin, Fundc1, LC3II, Atg5, Mfn2, Mfn1 in renal tubular cell of diabetic rats were decreased significantly. Calcitriol treatment reduced the levels of urinary albumin, serum creatinine and attenuated renal tubulointerstitial fibrosis in STZ induced diabetic rats. In addition, VDR agonist relieved mitophagy dysfunction, MAMs integrity, and inhibited mitochondrial fission, mitochondrial ROS. Co-immunoprecipitation analysis demonstrated that VDR interacted directly with Mfn2. Mitochondrial function including mitophagy, mitochondrial membrane potential (MMP), mitochondrial Ca2+, mitochondrial ATP and Complex V activity were decreased dramatically in HK-2 cells under HG/TGF-β ambience. In vitro pretreatment of HK-2 cells with autophagy inhibitor 3-MA, VDR siRNA or Mfn2 siRNA negated the activating effects of paricalcitol on mitochondrial function. Pricalcitol and VDR over-expression plasmid activated Mfn2 and then partially restored the MAMs integrity. Additionally, VDR restored mitophagy was partially associated with MAMs integrity through Fundc1.
CONCLUSION: Activated VDR could contribute to restore mitophagy through Mfn2-MAMs-Fundc1 pathway in renal tubular cell. VDR could recover mitochondrial ATP, complex V activity and MAMs integrity, inhibit mitochondrial fission and mitochondrial ROS. It indicating that VDR agonists ameliorate renal tubulointerstitial fibrosis in diabetic rats partially via regulation of mitochondrial function.
Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
In this study, the recombinant human hyaluronidase PH20 and neutral hyaluronidase (PH20) of bovine testicular sperm acrosomes were used to cleave macromolecular HA. Regardless of the cutting time, the HA fragment HA35, with an average molecular weight of 35 kDa, was produced (Registration number L20200708MP07707, Ministry of Health, Mongolia). Hyaluronidase is often used to improve the penetration and absorption of other injectable drugs. Hyaluronidase injection is also used off label to degrade excessive components used in cosmetic injections, such as cross-linked macromolecular HA fillers (https://www.realself.com/news/hyaluronidase-dissolve-fillers). In this study, HA35 was prepared by mixing hyaluronidase extracted from bovine testis (hyaluronidase for injection, H31022111) and HA (sodium hyaluronate for injection, H20174089) at room temperature for 20 minutes. The analgesic effect of HA35 on herpes zoster and shoulder, neck, back, and temporal pain was studied. This was a single-arm, open-label prospective clinical study in which patients were evaluated before and after treatment.
Hepatic ischemia reperfusion (I/R) injury is a common clinical complication. X-box binding protein 1 (XBP1), as a critical regulator of the endoplasmic reticulum stress, has been implicated in a variety of diseases. In this study, we aimed to investigate the effects and the underlying mechanism of XBP1 in the progression of hepatic I/R injury. Hepatocyte-specific XBP1 knockout mice, multiple viral delivery systems and specific pharmacological inhibitors were applied in vivo in a partial hepatic I/R injury mouse model and in vitro in a cell model of hypoxia-reoxygenation (H/R) injury. Mitophagy and autophagic flux were evaluated and fluorescence resonance energy transfer (FRET) as well as immunoprecipitation were performed. The results demonstrated that reperfusion for 6 h represented a critical timepoint in hepatic I/R injury and resulted in significant intracellular mitochondrial dysfunction; led to the breakdown of hepatocytes accompanied by the highest expression levels of XBP1. Hepatocyte-specific XBP1 knockout alleviated hepatic I/R injury via enhanced mitophagy, as demonstrated by the reduction in hepatocellular damage/necrosis and increased expression of mitophagy markers. Mechanistically, XBP1 interacted with FoxO1 directly and catalyzed the ubiquitination of FoxO1 for proteasomal degradation. Targeting XBP1 by genetic or pharmacological techniques potentiated the protein levels of FoxO1, further promoting the activity of the PINK1/Parkin signaling pathway, thus augmenting mitophagy and exerting hepatoprotective effects upon I/R injury. In conclusion, the inhibition of XBP1 potentiated FoxO1-mediated mitophagy in hepatic I/R injury. Specific genetic and pharmacological treatment targeting XBP1 in the perioperative 6 h prior to reperfusion exerted beneficial effects, thus providing a novel therapeutic approach.
AIM: To provide a comprehensive review of guidelines from various professional organisations on the work-up and management of post-prostatectomy Incontinence (PPI).
MATERIALS AND METHODS: The following guidelines were included in this review: European Association of Urology (EAU 2023), American Urological Association/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (AUA/SUFU 2019), International Consultation on Incontinence (ICI, 2018), the Canadian Urological Association (CUA, 2012) and the Urological Society of India (USI, 2018).
RESULTS: In general, the guidelines concur regarding the significance of conducting a comprehensive history and physical examination for patients with post-prostatectomy incontinence (PPI). However, there are variations among the guidelines concerning the recommended additional investigations. In cases of troublesome PPI, male slings are typically recommended for mild to moderate urinary incontinence (UI), while artificial urinary sphincters are preferred for moderate to severe UI, although the precise definition of this severity remains unclear. The guidelines provided by AUA/SUFU and the ICI have offered suggestions for managing complications or persistent/recurrent UI post-surgery, though some differences can be observed within these recommendations as well.
CONCLUSION: This is a first of its kind review encompassing Guidelines on PPI spanning over a decade. Although guidelines share overarching principles, nuanced variations persist, posing challenges for clinicians. This compilation consolidates and highlights both the similarities and differences among guidelines, providing a comprehensive overview of PPI diagnosis and management for practitioners. It is our expectation that as more evidence emerges in this and other areas of PPI management, the guidelines will converge and address crucial patient-centric aspects.
A system, method and computer program product for forecasting one or more clinical pathways and resource requirements of at least one patient are provided. The system comprises an input module for receiving inputs pertaining to patient diagnostic data, the patient diagnostic data comprising information identified during diagnosis of the patient. The system also comprises a repository for storing data comprising at least one of patient data and pre-existing clinical pathways. The patient data comprises at least one of the patient diagnostic data received from the input module; patient historical data comprising historical treatment data of the patient and patient demographic data comprising demographic details of the patient. The system also comprises a clinical pathway forecasting module for forecasting clinical pathways by application of predetermined analytical models on the patient data and pre-existing clinical pathways. The system further comprises a resource requirement forecasting module for forecasting resource requirements of the patient.
The current literature shows the promise of magnetic resonance imaging (MRI) for assessing response to therapy in RA but the heterogeneity of the methodology and the semi-quantitative nature of the image analysis limits its applicability. To evaluate the ability of DCE-MRI to serve as a biomarker for treatment-induced changes in RA associated synovial inflammation, the reproducibility of the measurement and an effect size are required. Additional endpoints such as synovial volume, bone erosion progression and bone marrow edema-like changes may also prove useful for short-term assessment of a therapeutic intervention, but have not been explored in the context of a pharmacodynamic biomarker. It is therefore critical to conduct a carefully designed longitudinal study, focused on identifying the key parameters related to the instrumentation and data analysis, to fully evaluate the potential utility of MRI in an early clinical development setting. Importantly, this study will also demonstrate the feasibility of using DCE-MRI at multiple centers to acquire useful information that will drive program decisions.

Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.
Blood-derived preparations, including autologous or allogenic serum, umbilical cord serum/plasma, and platelet-rich plasma eye drops, contain various growth factors, cytokines, and immunoglobulins that resemble natural tears. These components play important roles in corneal cell migration, proliferation, and wound healing. Blood-derived eye drops have demonstrated clinical effectiveness across a spectrum of ocular surface conditions, encompassing dry eye disease, Sjögren's syndrome, graft-versus-host disease, and neuropathic corneal pain (NCP). Currently, management of NCP remains challenging. The emergence of blood-derived eye drops represents a promising therapeutic approach. In this review, we discuss the benefits and limitations of different blood-derived eye drops, their mechanisms of action, and treatment efficacy in patients with NCP. Several studies have demonstrated the clinical efficacy of autologous serum eye drops in relieving pain and pain-like symptoms, such as allodynia and photoallodynia. Corneal nerve parameters were also significantly improved, as evidenced by increased nerve fiber density, length, nerve reflectivity, and tortuosity, as well as a decreased occurrence of beading and neuromas after the treatment. The extent of nerve regeneration correlated with improvement in patient-reported photoallodynia. Cord plasma eye drops also show potential for symptom alleviation and corneal nerve regeneration. Future directions for clinical practice and research involve standardizing preparation protocols, establishing treatment guidelines, elucidating underlying mechanisms, conducting long-term clinical trials, and implementing cost-effective measures such as scaling up manufacturing. With ongoing advancements, blood-derived eye drops hold promise as a valuable therapeutic option for patients suffering from NCP.
Vitamin products in a dry, finely divided, free flowing, solid state, the particles of which comprise a water-insoluble, fat soluble, vitamin active component dispersed in a minute portions (as droplets or finely divided solid particles) within a carrier which is a solid matrix consisting essentially of a starch carboxylic ester resistant to water wetting, are prepared by a process which comprises (1) forming a colloidal solution of water and said starch ester by (a) prewetting a powder of said starch ester with a water-wetting agent therefore to form a prewetted powder (b) suspending the prewetted powder in water to form a suspension and (c) while agitating the suspension heating the same until said powder goes into colloidal solution, (2) dispersing said vitamin active component in said colloidal solution whereby a dispersion is formed and (3) converting said dispersion into dry, finely divided, free flowing, solid particles.  Examples of suitable water-wetting agents are methanol and ethanol.  The preferred carriers are those obtained by reacting starch (e.g. corn starch) with octenyl succinic anhydride and neutralising the product obtained with aluminium sulphate; these carriers are termed high viscosity, starch alumino-succinate esters. The carrier may also comprise an edible plasticizer, e.g. glucose or sucrose, and another compatible colloid, e.g. gelatin or a natural gum.  Vitamin active components specified are Vitamin A alcohol, Vitamin A esters, e.g. the acetate and palmitate esters, Vitamin A aldehyde, Vitamin D, Vitamin E, e.g. a -tocopheryl acetate, Vitamin K, carotene and their derivatives and mixtures thereof. Antioxidants and surfactants may also be included; specified antioxidants are tocopherols, butylated hydroxyanisole and butylated hydroxytoluene.
The invention provides a sun-proof makeup-fixing loose powder prepared from natural herbaceous plants and a preparation method thereof, and relates to the technical field of cosmetics. The paint specifically comprises the following components in parts by weight: 75-80 parts of porous corn starch; 5-6 parts of trollius chinensis bunge extract; 0.5-5 parts of cistanche deserticola extract; 0.5-5 parts of glycyrrhizin; 2-15 parts of loose powder matrix auxiliary material; 2-8 parts of an auxiliary agent; 20-50 parts of a solvent. The combination of the trollius chinensis bunge extract, the cistanche deserticola extract and the glycyrrhizin can enhance the ultraviolet resistance and the antioxidation of the foundation powder, synergistically inhibit the release of histamine which is a skin sensitizing substance and relieve skin allergic reaction. The porous corn starch is powder particles which are modified by biological enzyme and have porous structures, and can effectively load the active molecules. After the loose powder is made up, the porous corn starch powder can continuously absorb sebum secreted by the skin while slowly releasing active molecules, so that the mild and long-acting sun-screening and anti-aging skin-nourishing makeup-fixing loose powder is prepared. Further, the cosmetic process is simplified and the burden on the skin is reduced.
Patients undergo grid radiation therapy over a single fraction on day 1 and palliative radiation therapy over 5 fractions on days 2 and -1 post-grid in the absence of disease progression or unacceptable toxicity. Patients also receive SOC immunotherapy and undergo CT at the discretion of the physician and undergo blood sample collection throughout the study.
PROBLEM TO BE SOLVED: To obtain the subject composition and food free tram side actions and having excellent effect by including cultured fungus, cultured lactobacillus and yeast. SOLUTION: This composition and food contain cultured fungus such as cultured powder of Aspergillus oryzae NK, cultured lactobacillus such as cultured powder of Streptococcus faecalis and yeast. The composition is administered in the form of a solid or liquid preparation for oral administration at a daily rate of 1-10 g/head in 1-3 divided doses. It can be used in various food forms. The cultured product can be produced by culturing the microorganisms according to conventional method. Dry yeast described in Japanese Pharmacopoeia can be used as the yeast. The composition is effective for lowering the neutral fat and total cholesterol and remarkably improving the condition of hyperlipemia.
<P>PROBLEM TO BE SOLVED: To provide compounds and methods enhancing the amount of an agent delivered to a cell or a group of cells.  <P>SOLUTION: Methods and compositions for enhancing transfer of the agent into the cell are provided. The agent may include a polypeptide, a polynucleotide such as genes and antisense nucleic acid, and other molecules. In some embodiments, the agents are modulating agents able to modulate cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells and cells existing as a tissue or organ.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This is a randomized controlled study of a cognitive-behavioral, anger control training (ACT) in adolescents with Tourette Syndrome (TS) complicated by disruptive behavior. Disruptive behaviors in TS may take numerous forms including noncompliance, anger outbursts, and physical aggression. Anger outbursts in TS have been described as rage attacks or rage storms due to their high intensity and unpredictability in response to minimal provocation. Whether these behaviors are part of TS, related to comorbid conditions, or due to the burden of chronic illness is not clear. Nevertheless, these disruptive behaviors can result in significant functional impairment and often require clinical attention. The purpose of the ACT intervention is to improve the explosive and noncompliant behavior in adolescents with TS by enhancing affect regulation and social problem-solving skills. The treatment is based on anger control training which has been empirically supported for reducing aggressive behaviors and improving social functioning in aggressive youths. The primary outcome measures include the parent-rated Oppositional Defiant Scale and the Clinicians Global Improvement Score assessed by a clinician blind to treatment assignment.
A test kit is provided herein for qualitatively determining the quality of drinking water.  The test kit includes at least one test tube containing a predetermined amount of a composition comprising an anti-microbially-active protein which has been isolated from mussels, and a glycogen additive which is added to the isolated protein to produce an admixture containing the isolated protein and the glycogen additive, the glycogen additive being added in an amount so that the composition contains at least one molecule of added glycogen per molecule of anti-microbially-active protein which has been isolated from the mussels.  A marking on the test tube indicates a pre-determined volume in the test tube.  An indicator extends along the tube and indicates different qualities of water to be tested.  The water to be tested is placed into the tube in an amount corresponding to the pre-determined amount.  The tube is then shaken and allowed to rest.  The quality of the water being tested is determined by visually correlating the amount of precipitate within the test tube along the indicator.
Wegener Granulomatosis without treatment is life-threatening. The standard treatment with corticosteroids and cyclophosphamide is usually effective at controlling active disease. However, disease relapse is frequent and requires increased exposure to these toxic drugs. In other patients initiation or continuation of these standard drugs is contraindicated due to intolerable side effects. No well-established therapy is available for relapsing patients. They may suffer severe organ damage due to progressive disease, or may die. The proposed indication for gusperimus is the treatment of relapsing Wegener Granulomatosis. The aim of therapy with gusperimus is to induce and maintain remission thereby avoiding further cyclophosphamide and reducing corticosteroid exposure.
Nutritional therapy (NT) based on a controlled protein intake represents a cornerstone in managing chronic kidney disease (CKD). However, if a CKD patient is at the same time affected by cancer, oncologists and nutritionists tend to suggest a dietary regimen based on high protein intake to avoid catabolism and malnutrition. International guidelines are not clear when we consider onco-nephrological patients and, as a consequence, no clinical shared strategy is currently applied in clinical practice. In particular, no precise nutritional management is established in nephrectomized patients for renal cell carcinoma (RCC), a specific oncological cohort of patients whose sudden kidney removal forces the remnant one to start a compensatory mechanism of adaptive hyperfiltration. Our study aimed to investigate the efficacy of a low-normal-protein high-calorie (LNPHC) diet based on a Mediterranean model in a consecutive cohort of nephrectomized RCC patients using an integrated nephrologist and nutritionist approach. A consecutive cohort of 40 nephrectomized RCC adult (age > 18) patients who were screened for malnutrition (malnutrition screening tool, MST < 2) were enrolled in a tertiary institution between 2020 and 2022 after signing a specific informed consent form. Each patient underwent an initial nephrological and nutritional evaluation and was subsequently subjected to a conventional CKD LNPHC diet integrated with aproteic foods (0.8 g/Kg/die: calories: 30-35 kcal per kg body weight/die) for a period of 6 months (±2 months). The diet was structured after considering eGFR (CKD-EPI 2021 creatinine formula), comorbidities, and nutritional status. MST, body mass index (BMI), phase angle (PA), fat mass percentage (FM%), fat-free mass index (FFMI), body cell mass index (BCMI), extracellular/intracellular water ratio (ECW/ICW), extracellular matrix/body cell mass ratio (ECM/BCM), waist/hip circumference ratio (WHC), lab test exams, and clinical variables were examined at baseline and after the study period. Our results clearly highlighted that the LNPHC diet was able to significantly improve several nutritional parameters, avoiding malnutrition and catabolism. In particular, the LNPHC diet preserved the BCM index (delta on median, ΔM + 0.3 kg/m2) and reduced the ECM/BCM ratio (ΔM - 0.03 *), with a significant reduction in the ECW/ICW ratio (ΔM - 0.02 *), all while increasing TBW (ΔM + 2.3% *). The LNPHC diet was able to preserve FFM while simultaneously depleting FM and, moreover, it led to a significant reduction in urea (ΔM - 11 mg/dL **). In conclusion, the LNPHC diet represents a new important therapeutic strategy that should be considered when treating onco-nephrological patients with solitary kidney due to renal cancer.